Marker Therapeutics Inc (MRKR): Nice presentation on 038 and also the ne...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	13
Posts	1547
Boards Moderated	0
Alias Born	06/14/2018

microcapbiotech

Re: A deleted message

Tuesday, 04/30/2019 12:11:16 AM

Tuesday, April 30, 2019 12:11:16 AM

Nice presentation on 038 and also the newer 039.
I also don't understand why, if Marker can add up to 11 antigens (from 5), and already did the pre-clinical work (they said on 3-28), why they didn't do a more targeted cocktail for pancreatic cancer.
What really perplexes me is Marker as a stock, and it's current stock price, (you mentioned buying 10 or 20 shares).
You mention ALLO with a market cap of 3.6 billion and a pipeline that is mostly pre-clinical (behind Markers).
And FATE with a market cap of 1.1 billion and a pipeline that is mostly pre-clinical (behind Markers).
Then Cellectis with a market cap of 800+ million and a pipeline that is mostly pre-clinical (behind Markers).
And consider the many billions that KITE and JUNO got bought out for.
Markers 240 million market cap seems awful cheap to me considering their MultiTAA potential and their pipeline.